TIMP3 and head and neck squamous cell carcinoma: In patients with advanced head-and-neck squamous cell carcinoma (HNSCC) treated solely with radiotherapy, promoter hypermethylation-driven silencing of TIMP3, an inhibitor of matrix metalloproteinases, and CDH1 (cadherin 1), a calcium-dependent cell–cell adhesion protein, have been identified as markers to predict better therapeutic outcome [54].